2016 Hematological Malignancies

Nivolumab in r&r HL Durability of reponse

100

On treatment, ongoing response Off treatment without progression Progressive disease, following response or stable disease

50

0

–50

–100 Percent Change From Baseline in Target Lesions/Tumor Burden

0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102 108 114

 First occurrence of new lesion